ERBB2 and breast carcinoma: Treatment selection of advanced breast cancer is based on hormonal receptors at the protein levels rather than at the genotype level, according to the NCCN guidelines HR-positive patients will be given hormonal therapy whereas HR-negative or Her2+ and visceral metastasis patients will receive chemotherapy [9].